Get the Stockscreener App
38.84
1.73%
0.66
Xenon Pharmaceuticals Inc stock is traded at $38.84, with a volume of 1.19M.
It is up +1.73% in the last 24 hours and up +23.97% over the past month.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
See More
Previous Close:
$38.18
Open:
$38.62
24h Volume:
1.19M
Relative Volume:
1.04
Market Cap:
$2.99B
Revenue:
$13.17M
Net Income/Loss:
$-199.06M
P/E Ratio:
-14.18
EPS:
-2.74
Net Cash Flow:
$-156.53M
1W Performance:
+1.60%
1M Performance:
+23.97%
6M Performance:
-2.24%
1Y Performance:
+0.52%
1-Day Range:
$38.02
$39.58
1-Week Range:
$37.02
$39.58
52-Week Range:
$26.74
$46.00
Xenon Pharmaceuticals Inc Stock (XENE) Company Profile
Name
Xenon Pharmaceuticals Inc
Sector
Industry
Phone
(604) 484-3300
Address
200 - 3650 GILMORE WAY, BURNABY
Compare XENE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XENE
Xenon Pharmaceuticals Inc
|
38.84 | 2.92B | 13.17M | -199.06M | -156.53M | -2.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Xenon Pharmaceuticals Inc Stock (XENE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-25 | Initiated | Chardan Capital Markets | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jan-04-24 | Initiated | Citigroup | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-25-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-14-22 | Initiated | Goldman | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Nov-28-22 | Initiated | Wells Fargo | Overweight |
| Oct-19-22 | Initiated | Raymond James | Outperform |
| Aug-29-22 | Initiated | BofA Securities | Buy |
| Jul-21-22 | Initiated | JP Morgan | Overweight |
| Oct-28-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-02-20 | Initiated | SVB Leerink | Outperform |
| Jul-21-20 | Initiated | Needham | Buy |
| Jun-01-20 | Resumed | Jefferies | Buy |
| Mar-25-20 | Initiated | Wedbush | Outperform |
| Jan-08-20 | Initiated | William Blair | Outperform |
| Sep-20-19 | Initiated | Guggenheim | Buy |
| Aug-08-18 | Reiterated | Stifel | Buy |
| Mar-13-17 | Initiated | Jefferies | Buy |
| Oct-21-16 | Initiated | Stifel | Buy |
| Sep-26-16 | Initiated | Guggenheim | Buy |
| Apr-14-16 | Reiterated | Jefferies | Buy |
| Oct-30-15 | Resumed | Jefferies | Buy |
| Dec-02-14 | Initiated | Canaccord Genuity | Buy |
View All
Xenon Pharmaceuticals Inc Stock (XENE) Latest News
Published on: 2025-08-20 13:12:52 - beatles.ru
Can Xenon Pharmaceuticals Inc. sustain its profitability2025 Market WrapUp & Weekly Chart Analysis and Trade Guides - thegnnews.com
Can Traders Expect Breakout From Xenon Pharmaceuticals Inc. This WeekJuly 2025 Price Swings & Technical Buy Zone Confirmations - kangso.co.kr
Are Xenon Pharmaceuticals’ (XENE) Widening Losses Signaling a Pivotal Shift in R&D Strategy? - simplywall.st
Should you wait for a breakout in Xenon Pharmaceuticals Inc.Treasury Yields & Real-Time Stock Entry Alerts - Newser
Research Analysts Issue Forecasts for XENE FY2025 Earnings - Defense World
HC Wainwright Issues Negative Outlook for XENE Earnings - Defense World
Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus - MSN
Will a bounce in Xenon Pharmaceuticals Inc. offer an exitJuly 2025 Movers & Community Verified Swing Trade Signals - Newser
Identifying reversal signals in Xenon Pharmaceuticals Inc.Weekly Risk Summary & Capital Efficient Trading Techniques - Newser
Xenon targets NDA filing for azetukalner within 6 months of phase III readout while advancing late-stage neuropsychiatric programs - MSN
What is William Blair’s Forecast for XENE FY2027 Earnings? - Defense World
Xenon Pharmaceuticals Reports Q2 2025 Progress and Outlook - MSN
Why Xenon Pharmaceuticals’ Stock is Climbing - TipRanks
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q2 2025 Earnings Call Transcript - Insider Monkey
Xenon (XENE) Receives a Buy from RBC Capital - The Globe and Mail
Xenon Pharmaceuticals (NASDAQ:XENE) Receives Buy Rating from Chardan Capital - Defense World
Xenon Pharmaceuticals (NASDAQ:XENE) Price Target Cut to $55.00 by Analysts at Royal Bank Of Canada - Defense World
Xenon Pharmaceuticals Inc. Approaches Psychological Resistance LevelFed Meeting & Daily Stock Momentum Reports - beatles.ru
Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up on Analyst Upgrade - Defense World
Will Xenon Pharmaceuticals Inc. continue its uptrendQuarterly Investment Review & Intraday High Probability Alerts - Newser
Best data tools to analyze Xenon Pharmaceuticals Inc. stockFree Daily Top Performing Stock Insights - Newser
TD Cowen Reaffirms Their Buy Rating on Xenon (XENE) - The Globe and Mail
Xenon Completes Patient Recruitment for Phase 3 Study - The Globe and Mail
Xenon Pharmaceuticals: Azetukalner's 2026 Data Readouts and Multi-Indication Launch Potential - AInvest
Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release - Seeking Alpha
Catalyst Pharmaceuticals shares rise 2.54% intraday after Xenon Pharmaceuticals reports positive Phase 3 study progress and commercial leadership appointment. - AInvest
Xenon Pharmaceuticals shares rise 7.40% intraday after reporting positive Phase 3 study progress and commercial officer appointment. - AInvest
Xenon Pharma Q2 2025 Earnings Preview - MSN
RBC Capital Adjusts Price Target on Xenon Pharmaceuticals to $55 From $57, Maintains Outperform Speculative Risk Rating - MarketScreener
Deutsche Bank Adjusts Xenon Pharmaceuticals Price Target to $57 From $60, Maintains Buy Rating - MarketScreener
Xenon Pharmaceuticals: Promising Clinical Developments and Strategic Positioning Support Buy Rating - TipRanks
Xenon Pharmaceuticals shares rise 7.04% premarket after reporting positive Phase 3 study progress and commercial officer appointment. - AInvest
Xenon Pharmaceuticals: Q2 Earnings Snapshot - Huron Daily Tribune
Compass Pathways shares fall 2.53% premarket after Xenon Pharmaceuticals reports Q2 2025 financial results. - AInvest
Xenon Pharmaceuticals Inc (XENE) Q2 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance
Xenon Pharmaceuticals Inc (XENE) Q2 2025 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada
Xenon Pharmaceuticals Q2 2025 Earnings Call Transcript: Key Highlights - AInvest
Xenon Pharmaceuticals' Q2 2025: Navigating Contradictions in X-TOLE2 Enrollment, Dosing, and Safety Strategies - AInvest
Xenon Pharmaceuticals jumps after massive earnings beat By Investing.com - Investing.com South Africa
Is a relief rally coming for Xenon Pharmaceuticals Inc. holders5-Year Price Trend Summary and Analysis - Newser
Xenon Pharmaceuticals' Azetukalner: A High-Potential Biotech Catalyst Ahead of 2026 Topline Data - AInvest
Nova Ltd. shares rise 2.00% after-hours following Xenon's positive Phase 3 study updates and new appointments. - AInvest
Xenon Pharmaceuticals jumps after massive earnings beat - Investing.com
Transcript : Xenon Pharmaceuticals Inc., Q2 2025 Earnings Call, Aug 11, 2025 - MarketScreener
Has Xenon Pharmaceuticals Inc. found a price floorMomentum Prediction Based on AI Backtesting - Newser
Xenon Pharmaceuticals reports Q2 EPS $1.07 vs. (75c) last year - TipRanks
Xenon Pharmaceuticals Inc. SEC 10-Q Report - TradingView
Xenon Pharmaceuticals Q2 Loss Widens, CFO Changes Announced - AInvest
Xenon Pharmaceuticals' Q2 2025 Earnings: A Catalyst for Neuroscience Innovation and Shareholder Value - AInvest
Xenon Pharmaceuticals Q2 Loss Widens - MarketScreener
Xenon Pharmaceuticals Inc Stock (XENE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xenon Pharmaceuticals Inc Stock (XENE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GANNON STEVEN | Director |
May 14 '25 |
Option Exercise |
12.57 |
5,144 |
64,660 |
7,144 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Option Exercise |
17.76 |
22,468 |
399,032 |
53,770 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Option Exercise |
17.76 |
16,315 |
289,754 |
46,468 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Option Exercise |
17.76 |
16,217 |
288,014 |
47,519 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 24 '25 |
Sale |
40.20 |
22,468 |
903,214 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 27 '25 |
Sale |
40.50 |
16,315 |
660,806 |
31,302 |
| MORTIMER IAN | PRESIDENT & CEO |
Jan 23 '25 |
Sale |
40.08 |
16,217 |
649,977 |
31,302 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):